ALX Oncology Holdings is a holding company. Through its subsidiaries, Co. is a clinical stage immuno-oncology company. Co.'s primary program is a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Co.'s primary product candidate, ALX148, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastric/gastroesophageal junction and breast cancer. The ALXO stock yearly return is shown above.
The yearly return on the ALXO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ALXO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|